Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abercrombie & Fitch Co. (ANF) vs Becton Dickinson and Co (BDX) Price & Performance

Abercrombie & Fitch Co.
Becton Dickinson and Co

Price performance

Price movement over the last 24 hours

Key statistics

Abercrombie & Fitch Co. vs Becton Dickinson and Co — how do they compare? Abercrombie & Fitch Co. trades at $91.98 (market cap $4.14B), while Becton Dickinson and Co trades at $151.94 (market cap $41.87B). The key difference: Becton Dickinson and Co is far larger — about 10.1× Abercrombie & Fitch Co.'s market cap, and Becton Dickinson and Co pays a 2.76% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.

ANFBDX
Market Cap
$4.14B$41.87B
Sector
Consumer CyclicalHealth
52-Week High
$129.85$185.39
52-Week Low
$65.61$135.49
Enterprise Value
$4.81B$58.33B
Dividend Yield
2.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abercrombie & Fitch Co.

Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.

ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.

Becton Dickinson and Co

BDX trades at $151.94, up 0.72% on the day, with a bearish technical signal despite recent earnings beats. The stock is supported by consistent revenue growth, reaching $21.84B in 2025, and a forward P/E of 26.52. Analyst consensus is mixed with a $173.40 price target, and the company maintains a solid dividend, recently paying $1.05 per share. Cash flow trends show variability, with 2025 net cash flow negative $1.00B, though 2026 projects a positive $346M.

The outlook for BDX balances strong fundamentals against near-term headwinds. Revenue growth and strategic positioning in medical technology offer upside, but investor sentiment is cautious due to bearish technicals and margin pressures. Risks include hospital spending caution and competitive dynamics. The stock presents a hold case for long-term investors, with potential catalysts from continued earnings outperformance and innovation in healthcare technology.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.

Read more on ANF

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX